Table 2.
Baseline Gylcated Sphingolipids by disease progression status.
| Sphingolipid | Disease Progression* | |||
|---|---|---|---|---|
| Persistently Normal (n=354) | Macroalbuminuria (n=69) | Chronic Kidney Disease (n=36) | MA and CKD (n=27) | |
| Hexosyl- | ||||
| C14 | 10.6 (6.7) | 9.0 (3.6) | 9.4 (4.6) | 9.0 (4.4) |
| C16 | 1895.7 (651.8) | 1630.5 (570.5)Ɨ | 1765.4 (543.4) | 1686.2 (535.4) |
| C18 | 100.7 (91.9) | 103.7 (39.0) | 110.3 (39.3)Ɨ | 114.0 (43.4)Ɨ |
| C18:1 | 36.8 (37.4) | 51.6 (30.3)Ɨ | 51.4 (25.5)Ɨ | 54.5 (28.0)Ɨ |
| C20 | 83.4 (36.1) | 99.6 (42.9)Ɨ | 99.7 (43.9)Ɨ | 103.2 (46.2)Ɨ |
| C20:1 | 15.3 (20.7) | 17.6 (8.5)Ɨ | 18.6 (8.6)Ɨ | 18.8 (8.9)Ɨ |
| C22 | 1131.9 (456.5) | 1036.3 (352.9) | 1105.2 (382.0) | 1075.4 (357.1) |
| C22:1 | 107.8 (185.5) | 87.4 (30.3) | 89.9 (28.8) | 88.7 (28.7) |
| C24 | 1264.7 (499.8) | 1143.9 (3353.8) | 1199.7 (441.5) | 1163.4 (363.8) |
| C24:1 | 446.7 (476.6) | 413.0 (168.1) | 406.8 (168.3) | 407.9 (182.2) |
| C26 | 10.1 (4.3) | 12.8 (6.3)Ɨ | 12.9 (6.7)Ɨ | 13.2 (6.5)Ɨ |
| C26:1 | 6.6 (7.2) | 7.5 (4.2)Ɨ | 7.2 (3.9) | 7.3 (4.0) |
| Lactosyl- | ||||
| C14 | 129.8 (47.5) | 91.7 (36.1)Ɨ | 104.3 (43.9)Ɨ | 97.7 (44.5)Ɨ |
| C16 | 3979.9 (1454.4) | 2963.7 (1329.4)Ɨ | 3298.1 (1433.9)Ɨ | 3163.4 (1561.6)Ɨ |
| C18 | 183.3 (62.1) | 134.7 (76.6)Ɨ | 165.0 (97.7)Ɨ | 155.5 (100.4)Ɨ |
| C18:1 | 93.9 (37.3) | 90.2 (25.1) | 102.8 (32.7) | 98.7 (27.9) |
| C20 | 44.5 (22.6) | 45.5 (23.9) | 51.8 (32.3) | 46.8 (26.3) |
| C20:1 | 23.0 (11.9) | 20.2 (9.7) | 23.6 (10.9) | 21.9 (10.8) |
| C22 | 113.1 (52.6) | 102.7 (46.5) | 112.0 (56.9) | 103.4 (46.3) |
| C22:1 | 17.1 (9.2) | 29.3 (24.2)Ɨ | 30.8 (26.7)Ɨ | 31.8 (26.4)Ɨ |
| C24 | 206.5 (77.0) | 146.3 (76.8)Ɨ | 165.9 (89.1)Ɨ | 150.0 (86.7)Ɨ |
| C24:1 | 260.6 (107.1) | 217.6 (76.6)Ɨ | 227.0 (82.5) | 217.7 (83.3) |
| C26 | 3.9 (12.7) | 2.1 (2.3)Ɨ | 2.1 (1.9)Ɨ | 2.0 (2.0)Ɨ |
| C26:1 | 5.3 (2.5) | 3.7 (2.1)Ɨ | 4.0 (1.9)Ɨ | 3.5 (1.9)Ɨ |
*
Disease progression groups are not mutually exclusive; of the 432 participants with sphingolipid data, 78 participants progressed to either MA or CKD: 27 Progressed to Both MA and CDK while 42 progressed to only MA and 9 progressed to only CKD. Data shown as unadjusted means (standard deviation).
Ɨ
P<0.05 as compared to persistently normal participants.